Continued efficacy of neratinib in patients with HER2-positive (HER2+) early-stage breast cancer: final overall survival (OS) analysis from the randomized phase 3 ExteNET trial

• M. Martin,
• F.A. Holmes,
• B. Moy,
• J. Mansi,
• M. Gnant,
• M. Buyse,
• C. Barrios,
• R. Bryce,
• A. Wong,
• A. Chan

Affiliations

M. Martin

F.A. Holmes

B. Moy

J. Mansi

M. Gnant

M. Buyse

C. Barrios

R. Bryce

A. Wong

A. Chan